EP1013

EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes.

Product information

CAS Number: 223568-55-6

Molecular Weight: 382.38

Formula: C18H23FN2O6

Synonym:

F1013

Chemical Name: (3S)-3-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]-5-fluoro-4-oxopentanoic acid

Smiles: CC(C)[C@H](NC(=O)OCC1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)CF

InChiKey: LYBWGROBJJXCJJ-BBRMVZONSA-N

InChi: InChI=1S/C18H23FN2O6/c1-11(2)16(17(25)20-13(8-15(23)24)14(22)9-19)21-18(26)27-10-12-6-4-3-5-7-12/h3-7,11,13,16H,8-10H2,1-2H3,(H,20,25)(H,21,26)(H,23,24)/t13-,16-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (261.52 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversal rate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function.

References:

1. Emamaullee JA, et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes. 2008 Jun;57(6):1556-66.

Products are for research use only. Not for human use.